Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 8/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7242892 | 0.79 | BCHE (0.62) | KMT2A | |
| SCHEMBL7239158 | 0.79 | L3MBTL1 (0.45) | P2RX4KMT2ACACNA1B | |
| SCHEMBL10782060 | 0.77 | P2RX4 (1.00) | P2RX4KMT2ACACNA1HCACNA1B | |
| SCHEMBL479818 | 0.75 | P2RX4 (0.77) | P2RX4CACNA1HCACNA1B | |
| SCHEMBL4900173 | 0.70 | P2RX4 (0.68) | P2RX4 | |
| SCHEMBL6903165 | 0.69 | P2RX4 (0.69) | P2RX4 | |
| SCHEMBL5243016 | 0.68 | P2RX4 (0.69) | P2RX4 | |
| SCHEMBL30571652 | 0.68 | P2RX4 (0.69) | P2RX4 | |
| SCHEMBL8023047 | 0.67 | P2RX4 (0.63) | P2RX4 | |
| SCHEMBL3451033 | 0.67 | SMN1; SMN2 (0.75) | P2RX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6544986-B2 | Such as 5-(N,N-dibenzyl)aminocarbonyl-2-pyridone; enzyme inhibitors; for treatment of Alzheimer's disease | DALHOUSIE UNIVERSITY (CA) | 2003-04-08 | — | — | US | claimed |
| US-6544986-B2 | Such as 5-(N,N-dibenzyl)aminocarbonyl-2-pyridone; enzyme inhibitors; for treatment of Alzheimer's disease | DALHOUSIE UNIVERSITY (CA) | 2003-04-08 | — | — | US | disclosed |
| US-6436972-B1 | HETEROCYCLIC AMIDES, USED AS ANTICHOLINERGICS AND SERINE PROTEASE STIMULANTS, FOR PROPHYLAXIS OF ALZHEIMER'S DISEASE, GLIOMAS AND VISION DEFECTS | DALHOUSIE UNIVERSITY (CA) | 2002-08-20 | — | — | US | disclosed |
| US-20020049330-A1 | Novel pyridones and their use as modulators of serine hydrolase enzymes | DALHOUSIE UNIVERSITY | 2002-04-25 | — | — | US | disclosed |
| WO-2001077078-A1 | NOVEL PYRIDONES AND THEIR USE AS MODULATORS OF SERINE HYDROLASE ENZYMES | DALHOUSIE UNIVERSITY (CA) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049330-A1 | Novel pyridones and their use as modulators of serine hydrolase enzymes | BCHE, PRSS1, BACE1 | P2RX4 3629/4885KMT2A 3594/4885CACNA1H 2548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.